Yadav MP

References (8)

Title : Efficacy and Safety of [(177)Lu]Lu-DOTAGA.Glu.(FAPi)(2) Therapy in Patients with Sarcoma - Ballal_2025_J.Nucl.Med_66_1612
Author(s) : Ballal S , Sakir M , Chandekar KR , Rastogi S , Yadav MP , Roesch F , Tripathi M , Martin M , Bal C
Ref : J Nucl Med , 66 :1612 , 2025
Abstract :
PubMedSearch : Ballal_2025_J.Nucl.Med_66_1612
PubMedID: 40841150

Title : [(177)Lu]Lu-DOTAGA.Glu.(FAPi)(2) Radionuclide Therapy: a New Treatment Option for Patients with Glioblastoma Multiforme - Ballal_2024_Nucl.Med.Mol.Imaging_58_32
Author(s) : Ballal S , Yadav MP , Raju S , Roesch F , Martin M , Tripathi M , Bal C
Ref : Nucl Med Mol Imaging , 58 :32 , 2024
Abstract :
PubMedSearch : Ballal_2024_Nucl.Med.Mol.Imaging_58_32
PubMedID: 38261876

Title : Therapeutic potential of [(177)Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment - Yadav_2024_Eur.J.Nucl.Med.Mol.Imaging_51_805
Author(s) : Yadav MP , Ballal S , Martin M , Roesch F , Satapathy S , Moon ES , Tripathi M , Gogia A , Bal C
Ref : Eur J Nucl Med Mol Imaging , 51 :805 , 2024
Abstract :
PubMedSearch : Yadav_2024_Eur.J.Nucl.Med.Mol.Imaging_51_805
PubMedID: 37932560

Title : Head-to-Head Comparison between [(68)Ga]Ga-DOTA.SA.FAPi and [(18)F]F-FDG PET\/CT Imaging in Patients with Breast Cancer - Ballal_2023_Pharmaceuticals.(Basel)_16_
Author(s) : Ballal S , Yadav MP , Roesch F , Wakade N , Raju S , Sheokand P , Mishra P , Moon ES , Tripathi M , Martin M , Bal C
Ref : Pharmaceuticals (Basel) , 16 : , 2023
Abstract :
PubMedSearch : Ballal_2023_Pharmaceuticals.(Basel)_16_
PubMedID: 37111277

Title : Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics - Martin_2023_Cancers.(Basel)_15_
Author(s) : Martin M , Ballal S , Yadav MP , Bal C , Van Rymenant Y , De Loose J , Verhulst E , De Meester I , Van der Veken P , Roesch F
Ref : Cancers (Basel) , 15 : , 2023
Abstract :
PubMedSearch : Martin_2023_Cancers.(Basel)_15_
PubMedID: 36980775

Title : Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time - Moon_2021_Am.J.Nucl.Med.Mol.Imaging_11_476
Author(s) : Moon ES , Ballal S , Yadav MP , Bal C , Van Rymenant Y , Stephan S , Bracke A , Van der Veken P , De Meester I , Roesch F
Ref : Am J Nucl Med Mol Imaging , 11 :476 , 2021
Abstract :
PubMedSearch : Moon_2021_Am.J.Nucl.Med.Mol.Imaging_11_476
PubMedID: 35003886

Title : Biodistribution, pharmacokinetics, dosimetry of [(68)Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [(18)F]F-FDG PET\/CT in patients with various cancers - Ballal_2021_Eur.J.Nucl.Med.Mol.Imaging_48_1915
Author(s) : Ballal S , Yadav MP , Moon ES , Kramer VS , Roesch F , Kumari S , Tripathi M , ArunRaj ST , Sarswat S , Bal C
Ref : Eur J Nucl Med Mol Imaging , 48 :1915 , 2021
Abstract :
PubMedSearch : Ballal_2021_Eur.J.Nucl.Med.Mol.Imaging_48_1915
PubMedID: 33244617

Title : Biodegradability and biodegradation pathway of di-(2-ethylhexyl) phthalate by Burkholderia pyrrocinia B1213 - Li_2019_Chemosphere_225_443
Author(s) : Li J , Zhang J , Yadav MP , Li X
Ref : Chemosphere , 225 :443 , 2019
Abstract :
PubMedSearch : Li_2019_Chemosphere_225_443
PubMedID: 30897469